For research use only. Not for therapeutic Use.
YKL-06-062 is a second-generation salt-inducible kinase (SIK) inhibitor with an IC50 of 2.12 nM/1.40 nM/2.86 nM for SIK1, SIK2 and SIK3, respectively[1].
YKL 06-062 (0.0004-16 μM; 3 hours) increases MITF mRNA expression in a dose-dependent manner[1].
| Catalog Number | I017817 |
| CAS Number | 2172617-16-0 |
| Synonyms | 1-cyclohexyl-3-(2,6-dimethylphenyl)-7-[4-(4-methylpiperazin-1-yl)anilino]-4H-pyrimido[4,5-d]pyrimidin-2-one |
| Molecular Formula | C31H39N7O |
| Purity | ≥95% |
| InChI | InChI=1S/C31H39N7O/c1-22-8-7-9-23(2)28(22)37-21-24-20-32-30(34-29(24)38(31(37)39)27-10-5-4-6-11-27)33-25-12-14-26(15-13-25)36-18-16-35(3)17-19-36/h7-9,12-15,20,27H,4-6,10-11,16-19,21H2,1-3H3,(H,32,33,34) |
| InChIKey | GFXPGVPPWWPDPV-UHFFFAOYSA-N |
| SMILES | CC1=C(C(=CC=C1)C)N2CC3=CN=C(N=C3N(C2=O)C4CCCCC4)NC5=CC=C(C=C5)N6CCN(CC6)C |
| Reference | [1]. Mujahid N, et al. A UV-Independent Topical Small-Molecule Approach for Melanin Production in Human Skin. Cell Rep. 2017 Jun 13;19(11):2177-2184. |
